Anti Sm - Antibody, in Visit Clinic

Anti‑Sm antibody is an autoantibody directed against Smith (Sm) ribonucleoproteins. It is highly specific for systemic lupus erythematosus (SLE) — present in roughly 10–30% of patients — and supports diagnosis when positive. Its presence can be linked with more severe disease, including renal and central nervous system involvement, and is detected by serologic immunoassays.

Positive SM (smear‑positive) means sputum microscopy shows acid‑fast bacilli, indicating active pulmonary tuberculosis. It implies the person is likely infectious and needs prompt anti‑TB treatment, contact tracing, and follow‑up. Additional tests (culture or molecular assays) confirm diagnosis and drug susceptibility. Isolation precautions continue until effective therapy substantially reduces infectiousness.

Anti‑Smith (Sm) antibodies are highly specific for systemic lupus erythematosus (SLE) and are used diagnostically. They are uncommon in other conditions but can occasionally appear in mixed connective tissue disease, primary Sjögren’s syndrome, or systemic sclerosis. Presence of anti‑Sm often correlates with more severe SLE manifestations, including renal and central nervous system involvement.

"Anti‑Sm antibody hepatitis" refers to liver inflammation occurring in people who have anti‑Smith (anti‑Sm) antibodies, which are specific markers of systemic lupus erythematosus (SLE). This usually indicates lupus‑related liver involvement (lupus hepatitis) rather than classic autoimmune hepatitis. It typically causes mild–moderate transaminase elevation; diagnosis uses serology, liver tests and sometimes biopsy. Treatment targets underlying SLE with immunosuppression.

SM on an ANA panel refers to anti‑Smith (anti‑Sm) antibodies, which target small nuclear ribonucleoprotein complexes. Anti‑Sm is highly specific for systemic lupus erythematosus (SLE) but occurs in only a minority of patients, so a positive test strongly supports SLE while a negative test does not rule it out. It’s usually confirmed by immunoassay or immunoblot.

No single test alone confirms lupus. Diagnosis depends on clinical features plus laboratory tests. ANA is a sensitive screening test; more specific markers are anti–double‑stranded DNA (anti‑dsDNA) and anti‑Smith (anti‑Sm) antibodies. Complement levels (C3/C4), urine tests for kidney involvement, and sometimes a kidney biopsy (for suspected lupus nephritis) help confirm disease and assess severity.